| http://www.w3.org/ns/prov#value | - With this safety profile, the drug is an excellent candidate for use in combination therapy with other types of cancer therapies, particularly first-line regimens.RTA 402 is currently being tested in a Phase 1/2 clinical study, in combination with standard therapy, in patients with pancreatic cancer.
|
